Celldex Therapeutics financials
$31.49+1.25%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.0K | $15.0K | $121.0K | $0.00 | $730.0K | $695.0K | $1.2M | $3.2M | $2.5M | $156.0K | $4.1M | $1.5M |
| Gross profit | $22.0K | $15.0K | $121.0K | $0.00 | $730.0K | $695.0K | $1.2M | $3.2M | $2.5M | $156.0K | $4.1M | $1.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$80.6M | -$84.4M | -$87.2M | -$73.6M | -$63.9M | -$62.7M | -$56.0M | -$52.1M | -$46.3M | -$40.6M | -$47.6M | -$41.2M |
| Net income | -$73.5M | -$78.7M | -$81.3M | -$67.0M | -$56.6M | -$53.8M | -$47.1M | -$42.1M | -$35.8M | -$32.8M | -$43.3M | -$38.3M |
| Net margin | −334104.5% | −524566.7% | −67204.1% | — | −7753.4% | −7740.4% | −4007.8% | −1320.0% | −1434.8% | −21030.8% | −1048.3% | −2522.1% |
| Diluted EPS | $-0.94 | $-1.18 | $-1.22 | $-1.01 | $-0.85 | $-0.81 | $-0.71 | $-0.64 | $-0.54 | $-0.56 | $-0.83 | $-0.81 |
| EBITDA | -$79.7M | -$83.6M | -$86.3M | -$72.8M | -$63.0M | -$61.9M | -$55.2M | -$51.3M | -$45.5M | -$39.8M | -$34.4M | -$40.5M |
| Operating cash flow | -$57.4M | -$65.6M | -$63.9M | -$48.6M | -$44.0M | -$54.4M | -$32.5M | -$55.3M | -$29.3M | -$40.6M | -$32.5M | -$19.0M |
| Free cash flow | -$60.6M | -$67.2M | -$65.2M | -$49.1M | -$44.7M | -$54.6M | -$33.2M | -$55.9M | -$29.6M | -$41.0M | -$33.2M | -$19.1M |
| Diluted shares | 77.8M | 66.6M | 66.5M | 66.4M | 66.4M | 66.4M | 66.4M | 66.3M | 66.0M | 58.9M | 52.1M | 47.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $47.5M | $35.7M | $28.9M | $36.0M | $23.0M | $17.1M |
| Short-term investments | $670.1M | $415.7M | $489.7M | $547.2M | $607.3M | $656.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $782.3M | $511.3M | $583.0M | $648.4M | $692.4M | $739.5M |
| Total liabilities | $67.8M | $55.0M | $55.8M | $50.1M | $37.0M | $36.5M |
| Shareholders' equity | $714.6M | $456.2M | $527.2M | $598.4M | $655.4M | $703.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology